Innovations and Future Directions in Higher Risk MDS Treatments

Video content above is prompted by the following:

• What are the key challenges in developing effective therapies for patients with TP53-mutated higher-risk myelodysplastic syndromes (MDS), and what strategies are being explored to address these challenges?
• What innovations in the pipeline for higher-risk MDS treatments are you most excited about? What role do you think novel targeted therapies and/or combination therapy will have in future MDS treatment paradigms?